

一般口演をされる方は皆様、ポスターも作成いただく必要があります。
それぞれの言語は以下のとおりでお願いいたします。

- ・一般口演：日本語
- ・一般口演用スライド：英語
- ・ポスター：英語

10:00～11:00 Tumor microenvironment and regulation of the immune system(I)

Chairs: Heiichiro Udono, Okayama University Graduate School of Medicine, Japan
Mamoru Harada, Shimane University Faculty of Medicine, Japan

10:00 A1-1 Mitsuyo Yoshida, The University of Tokyo, Japan

Inflammation and the modulation of tumor microenvironment in ovarian cancer with peritoneal carcinomatosis

A1-2 Koji Fujieda, Kumamoto University, Japan

Myeloid cells derived soluble IL-6 receptor (sIL-6R) attenuates Th1 differentiation of tumor-specific CD4+ T cells to exacerbate tumor outgrowth

A1-3 Hirotsugu Nagase, WPI Immunology Frontier Research Center, Japan

Microbiota modulate colorectal cancer microenvironment and develop two immunologically different tumors

A1-4 Burcu Temizoz, Osaka University, Japan

TLR9 and STING Agonists Synergistically Induce Innate and Adaptive Type-II IFN

A1-5 Yuya Terashima, The University of Tokyo, Japan

A chemokine receptor-associating molecule FROUNT is required for macrophage infiltration and tumor progression

A1-6 Kimihiro Yamashita, Kobe University Graduate School of Medicine, Japan

Early-phase administration of low-dose 5-fluorouracil and early-phase resection of the established melanoma prevents the formation of lung metastases by inhibiting MDSC generation and accumulation

A1-7 Muhammad Baghdadi, Hokkaido University, Japan

Chemotherapy-induced IL-34 accelerates the formation of tumor associated macrophages (TAMs) in human tumor microenvironment

A1-8 Yusuke Sato, RIKEN Center for Integrative Medical Science, Yokohama, Kanagawa, Japan

Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma

11:00～12:00 Tumor microenvironment and regulation of the immune syst (II)

Chairs: Hiroyoshi Nishikawa, National Cancer Center, Japan
Kiyoshi Yoshimura, National Cancer Center, Japan

11:00 A2-1 Tomonari Kinoshita, Keio University School of Medicine, Japan

Differential prognostic roles of tumor infiltrating lymphocyte in patients with resected non-small cell lung cancer

A2-2 Kayoko Waki, Kurume University Research Center for Innovative Cancer Therapy, Japan

Feasibility study of personalized peptide vaccination for cervical cancer patients who have received prior cisplatin-based chemotherapy

A2-3 Satoshi Ueha, The University of Tokyo, Japan

Robust anti-tumor CD8⁺T cell responses elicited by the anti-CD4 depleting antibody therapy

A2-4 Shingo Eikawa, Okayama University, Japan

Metformin administration stimulates glycolysis of effector memory CD8TIL in tumor microenvironment

A2-5 Haruka Shinohara, Gifu University, Japan

The regulated polarization of tumor-associated macrophages by secretions from cancer cells

A2-6 Fumiyasu Momose, Mie University Graduate School of Medicine, Japan

Selectivity and tumoricidal activity of the guanine-rich miRNAs in the human cytotoxic CD8⁺ T cell-released exosomes

A2-7 Hidemitsu Kitamura, Hokkaido University, Japan

MicroRNA as a novel biomarker for development of personalized medicine in personalized cancer immunotherapy

A2-8 Shoichi Hazama, Yamaguchi University Graduate School of Medicine, Japan

A comparison of miRNA expression levels between colorectal cancer tissues and normal colorectal tissues of patients treated with peptide vaccine

13:30~14:30 Tumor antigens and cancer vaccine

Toshihiko Torigoe, Sapporo Medical University School of Medicine, Japan

Tetsuro Sasada, Kanagawa Cancer Center, Japan

13:30 B-1 Sho Miyamoto, Sapporo Medical University School of Medicine, Japan

A novel immunogenic peptide that is naturally processed and presented by HLA-A24 of human colon cancer stem cells

B-2 Hironori Otaka, Medical & Biological Laboratories Co., Ltd., Japan

Identification of a novel HLA-A*24:02-restricted CTL epitope from cytoskeleton-associated protein 4 (CKAP4)

B-3 Takashi Fukuyama, Kitasato University Medical Center, Japan

The characteristics of a cancer/testis antigen, KK-LC-1.

B-4 Masatoshi Hirayama, Kumamoto University, Japan

Identification of oncofetal antigen (IMP-3)-derived long peptides encompassing both CTL epitopes and multiple HLA class II-restricted Th cell epitopes

B-5 Takahiro Karasaki, The University of Tokyo Hospital, Japan

In silico prediction of neoantigen for lung cancer targeting shared somatic mutations

B-6 Masanori Fuse, National Cancer Center, Japan

The induction of cancer stem-like cells from human colon cancer and the search for its cell surface markers

B-7 Yu Sawada, National Cancer Center, Japan

GPC3 expression could be the biomarker of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients: Results from phase II trial.

14:30~15:30 Anti-tumor effector cell (I)

Chairs: Hiroaki Ikeda, Mie University Graduate School of Medicine, Japan

Shin-ichiro Fujii, RIKEN Center for Integrative Medical Sciences (IMS), Japan

14:30 C1-1 Tatsushi Naito, Kanazawa University, Japan

High-dose cyclophosphamide induces specific tumor immunity by rapid recruitment of CD4-positive cytolytic T cells into tumor sites

C1-2 Taisuke Kondo, Keio University School of Medicine, Japan

Mouse CD4+ stem cell memory T cells generated by Notch signaling control tumor progression

C1-3 Hajime Kamiyuku, Keio University School of Medicine, Japan

Berberine has direct enhancing activities on anti-tumor memory and effector T cells

C1-4 Kenji Murata, Sapporo Medical University, Japan

Identification of a novel human T cell population with the characteristics of stem cell memory

C1-5 Koji Nagaoka, The University of Tokyo Hospital, Japan

Most of the CD8+ tumor-infiltrating lymphocytes are reactive to tumors in spontaneously regressing or progressing murine gastric cancer

C1-6 Yujiro Toyoshima, Hokkaido University, Japan

Crucial roles of IL-6 in suppression of antitumor immune responses under tumor microenvironments

C1-7 Takashi Inozume, University of Yamanashi

CD155-TIGIT interaction is an immune checkpoint regulating antimelanoma TIL responses

C1-8 Fumie Ihara, Chiba University

Analysis of regulatory T cells in peripheral blood of the patients with Head and Neck cancer and their inhibitory role on NKT cells.

16:00~17:00 Anti-tumor effector cell (II)

Chairs: Kiyotaka Kuzushima, Aichi Cancer Center Research Institute, Japan

Hiroshi Fujiwara, Ehime University, Japan

16:00 C2-1 Nicholas Casey, Ehime University, Japan

Targeting Aurora Kinase A utilising an Improved TCR Gene-transfer Vector

C2-2 Naoki Kunii, Chiba University, Japan

Antigen Specific Immunotherapy Based on Chimeric Antigen Receptor Expressing T Cells Targeted to Salivary Gland Tumor

C2-3 Keishi Adachi, Yamaguchi University Graduate School of Medicine, Japan

Development of functionally improved, novel chimeric antigen receptor-expressing T cells against

tumors

C2-4 Yasushi Akahori, Mie University Graduate School of Medicine, Japan

Development of immunotherapy with chimeric antigen receptor targeting intracellular WT1 gene product presented on HLA-A*24:02 molecule

C2-5 Kota Iwahori, Osaka University Graduate School of Medicine, Japan

Engager T cells: a new class of antigen-specific T cells with stimulation of bystander T cells

C2-6 Takuya Maeda, Kyoto University, Japan

Regeneration of tumor specific CTLs utilizing iPS technology

C2-7 Seiji Nagano, Kyoto University, Japan

Regeneration of MART-1 specific T cells from T-iPS cells for allogeneic transplantation

C2-8 Satoru Senju, Kumamoto University Graduate School of Medical Sciences, Japan

Cancer therapy with ES cell-derived macrophages producing interferon in a mouse model

17:00~18:00 Clinical trials, immunomonitoring and biomarkers

Chairs: Akira Yamada, Kurume University, Research Center for Innovative Cancer Therapy, Japan
Shinichi Kageyama, Mie University Graduate School of Medicine, Japan

17:00 D-1 Takashi Akazawa, Osaka Medical Center for Cancer and Cardiovascular diseases, Japan

Development of bacteria-mimicked tumor cell vaccine modified with engineered TLR2 ligands

D-2 Hiroaki Shime, Hokkaido University Graduate School of Medicine, Japan

Toll-like receptor 2 enhances immunosuppressive activity of myeloid-derived suppressor cells

D-3 Keitaro Fukuda, Keio University School of Medicine, Japan

Phase I/II pilot study of peptide-pulsed dendritic cell vaccination in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma

D-4 Yoshiko Hashii, Department of Pediatrics Osaka University Graduate School of Medicine, Japan

WT1 vaccination in pediatric rhabdomyosarcoma

D-5 Ako Hosono, National Cancer Center Hospital East, Japan

Phase I study of vaccine therapy with a cocktail of peptides for pediatric patients with refractory solid tumors

D-6 Naohiro Seo, Mie University Graduate School of Medicine, Japan

Tumor-infiltrating CD8+ T cell-released exosomes interrupt tumor progression by depleting fibroblastic mesenchymal tumor stroma

D-7 Daisuke Muraoka, Mie University Graduate School of Medicine, Japan

Signal-transducing Adaptor Protein-2 enhances the STAT3 signaling and prevents exhaustion of the Long-term Memory T Cells.

D-8 Toshiaki Yasuoka, Ehime University Graduate School of Medicine, Japan

The transcriptional repressor Gfi1 is critical for invariant NKT cell development and effector function

Program Committee

Hideo Yagita, Juntendo University, Japan

Miyuki Azuma, Tokyo Medical and Dental University, Japan

Kazunori Kato, Toyo University, Japan

Kazuhiro Kakimi, The University of Tokyo, Japan